Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis
- 15 June 2015
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 308 (12) , H1564-H1574
Abstract
Tetrandrine (TTD) is a calcium channel blocker with documented antifibrotic actions. In this study, for the first time, we identified that TTD can directly prevent in vitro human cardiac myofibroblast activation and limit in vivo myocardial fibrosis. In vitro, cardiac myofibroblasts from human atrial biopsies ( N = 10) were seeded in three-dimensional collagen matrices. Cell-collagen constructs were exposed to transforming growth factor-β1(10 ng/ml), with or without TTD (1 and 5 μM) for 48 h. Collagen gel contraction, myofibroblast activation (α-smooth muscle actin expression), expression of profibrotic mRNAs, and rate of collagen protein synthesis were compared. TTD decreased collagen gel contraction (79.7 ± 1.3 vs 60.1 ± 8.9%, P < 0.01), α-smooth muscle actin expression (flow cytometry), collagen synthesis ([3H]proline incorporation), and collagen mRNA expression. Cell viability was similar between groups (annexin positive cells: 1.7 vs. 1.4%). TTD inhibited collagen gel contraction in the presence of T-type and L-type calcium channel blockers, and the intracellular calcium chelator BAPTA-AM (15 μM), suggesting that the observed effects are not mediated by calcium homeostasis. In vivo, Dahl salt-sensitive hypertensive rats were treated with variable doses of TTD (by intraperitoneal injection over 4 wk) and compared with untreated controls ( N = 12). Systemic blood pressure was monitored by tail cuff. Myocardial fibrosis and left ventricular compliance were assessed by histology and passive pressure-volume analysis. Myocardial fibrosis was attenuated compared with untreated controls (%collagen area: 9.4 ± 7.3 vs 2.1 ± 1.0%, P < 0.01). Left ventricular compliance was preserved. In conclusion, TTD reverses human cardiac myofibroblast activation and myocardial fibrosis, independent of calcium channel blockade.Keywords
This publication has 34 references indexed in Scilit:
- Congestive Heart Failure Effects on Atrial Fibroblast Phenotype: Differences between Freshly-Isolated and Cultured CellsPLOS ONE, 2012
- Effect of tetrandrine on the TGF-β-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitroBurns, 2012
- Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillationCardiovascular Research, 2010
- Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species‐dependent ERK1/2 signallingBritish Journal of Pharmacology, 2010
- Tetrandrine Suppresses Activation of Human Subconjunctival FibroblastsIn VitroCurrent Eye Research, 2008
- The MyofibroblastThe American Journal of Pathology, 2007
- Is the area under blood pressure curve the best parameter to evaluate 24-h ambulatory blood pressure monitoring data?Blood Pressure Monitoring, 2005
- Antihypertensive and anti-arrhythmic effects of an extract of Radix Stephaniae Tetrandrae in the ratJournal of Pharmacy and Pharmacology, 2004
- Tetrandrine: A new ligand to block voltage-dependent Ca2+ and Ca2+-activated K+ channelsLife Sciences, 1994
- Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusionInternational Journal of Cardiology, 1993